{"id":19187,"date":"2024-09-16T16:39:20","date_gmt":"2024-09-16T19:39:20","guid":{"rendered":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\/"},"modified":"2024-09-16T16:39:20","modified_gmt":"2024-09-16T19:39:20","slug":"relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha","status":"publish","type":"ensaio_clinico","link":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\/","title":{"rendered":"RELATIVITY-127 &#8211; Melanoma irressec\u00e1vel ou metast\u00e1tico \u2013 1\u00aa linha"},"content":{"rendered":"<p><span data-contrast=\"auto\">Combina\u00e7\u00e3o de Nivolumabe + Relatlimabe via subcut\u00e2nea versus a combina\u00e7\u00e3o de Nivolumabe + Relatlimabe via intravenosa<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">&nbsp;<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Popula\u00e7\u00e3o: <\/span><\/b><span data-contrast=\"auto\">Idade <\/span><span data-contrast=\"auto\">&gt;<\/span><span data-contrast=\"auto\"> 12 anos; Melanoma em est\u00e1gio III (irressec\u00e1vel) ou IV (metast\u00e1tico) confirmado histologicamente. Os participantes n\u00e3o devem ter sido tratados anteriormente. Terapias adjuvantes ou neoadjuvantes pr\u00e9vias s\u00e3o permitidas. Doen\u00e7a mensur\u00e1vel conforme RECIST v1.1. Tecido tumoral dispon\u00edvel para an\u00e1lise central (at\u00e9 3 meses antes da triagem).<\/span><\/p>\n<p><span class=\"TextRun SCXW61082614 BCX0\" lang=\"PT-BR\" xml:lang=\"PT-BR\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW61082614 BCX0\">Clinical <\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW61082614 BCX0\">Trials<\/span><span class=\"NormalTextRun SCXW61082614 BCX0\">: <\/span><\/span><span class=\"TextRun SCXW61082614 BCX0\" lang=\"PT-BR\" xml:lang=\"PT-BR\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW61082614 BCX0\">NCT05625399<\/span><\/span><span class=\"EOP SCXW61082614 BCX0\" data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">&nbsp;<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Combina\u00e7\u00e3o de Nivolumabe + Relatlimabe via subcut\u00e2nea versus a combina\u00e7\u00e3o de Nivolumabe + Relatlimabe via intravenosa&nbsp; Popula\u00e7\u00e3o: Idade &gt; 12 anos; Melanoma em est\u00e1gio III (irressec\u00e1vel) ou IV (metast\u00e1tico) confirmado histologicamente. Os participantes n\u00e3o devem ter sido tratados anteriormente. Terapias adjuvantes ou neoadjuvantes pr\u00e9vias s\u00e3o permitidas. Doen\u00e7a mensur\u00e1vel conforme RECIST v1.1. Tecido tumoral dispon\u00edvel para [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-19187","ensaio_clinico","type-ensaio_clinico","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>RELATIVITY-127 - Melanoma irressec\u00e1vel ou metast\u00e1tico \u2013 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino<\/title>\n<link rel=\"canonical\" href=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RELATIVITY-127 - Melanoma irressec\u00e1vel ou metast\u00e1tico \u2013 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta property=\"og:description\" content=\"Combina\u00e7\u00e3o de Nivolumabe + Relatlimabe via subcut\u00e2nea versus a combina\u00e7\u00e3o de Nivolumabe + Relatlimabe via intravenosa&nbsp; Popula\u00e7\u00e3o: Idade &gt; 12 anos; Melanoma em est\u00e1gio III (irressec\u00e1vel) ou IV (metast\u00e1tico) confirmado histologicamente. Os participantes n\u00e3o devem ter sido tratados anteriormente. Terapias adjuvantes ou neoadjuvantes pr\u00e9vias s\u00e3o permitidas. Doen\u00e7a mensur\u00e1vel conforme RECIST v1.1. Tecido tumoral dispon\u00edvel para [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\/\" \/>\n<meta property=\"og:site_name\" content=\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\\\/\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\\\/\",\"name\":\"RELATIVITY-127 - Melanoma irressec\u00e1vel ou metast\u00e1tico \u2013 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\"},\"datePublished\":\"2024-09-16T19:39:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensaios Cl\u00ednicos\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"RELATIVITY-127 &#8211; Melanoma irressec\u00e1vel ou metast\u00e1tico \u2013 1\u00aa linha\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/\",\"name\":\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ptbr.idor.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RELATIVITY-127 - Melanoma irressec\u00e1vel ou metast\u00e1tico \u2013 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","canonical":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\/","og_locale":"pt_BR","og_type":"article","og_title":"RELATIVITY-127 - Melanoma irressec\u00e1vel ou metast\u00e1tico \u2013 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","og_description":"Combina\u00e7\u00e3o de Nivolumabe + Relatlimabe via subcut\u00e2nea versus a combina\u00e7\u00e3o de Nivolumabe + Relatlimabe via intravenosa&nbsp; Popula\u00e7\u00e3o: Idade &gt; 12 anos; Melanoma em est\u00e1gio III (irressec\u00e1vel) ou IV (metast\u00e1tico) confirmado histologicamente. Os participantes n\u00e3o devem ter sido tratados anteriormente. Terapias adjuvantes ou neoadjuvantes pr\u00e9vias s\u00e3o permitidas. Doen\u00e7a mensur\u00e1vel conforme RECIST v1.1. Tecido tumoral dispon\u00edvel para [&hellip;]","og_url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\/","og_site_name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\/","url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\/","name":"RELATIVITY-127 - Melanoma irressec\u00e1vel ou metast\u00e1tico \u2013 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","isPartOf":{"@id":"https:\/\/ptbr.idor.org\/#website"},"datePublished":"2024-09-16T19:39:20+00:00","breadcrumb":{"@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/relativity-127-melanoma-irressecavel-ou-metastatico-1a-linha\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ptbr.idor.org\/"},{"@type":"ListItem","position":2,"name":"Ensaios Cl\u00ednicos","item":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/"},{"@type":"ListItem","position":3,"name":"RELATIVITY-127 &#8211; Melanoma irressec\u00e1vel ou metast\u00e1tico \u2013 1\u00aa linha"}]},{"@type":"WebSite","@id":"https:\/\/ptbr.idor.org\/#website","url":"https:\/\/ptbr.idor.org\/","name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ptbr.idor.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"}]}},"_links":{"self":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico\/19187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico"}],"about":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/types\/ensaio_clinico"}],"wp:attachment":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/media?parent=19187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}